

**MARCH 20, 2023**

For more information,  
contact:

Ulf H. Grundmann  
+49 69 257 811 400  
[ugrundmann@kslaw.com](mailto:ugrundmann@kslaw.com)

Elisabeth Kohoutek  
+49 69 257 811 401  
[ekohoutek@kslaw.com](mailto:ekohoutek@kslaw.com)

---

King & Spalding

Frankfurt  
TaunusTurm  
Taunustor 1  
60310 Frankfurt am Main  
Tel: +49 69 257 811 000

## Medical Devices in the EU: MDD Certificates Remain Valid - the EU Extends Transition Periods for MDR Compliance, and Sell-Off Dates for Devices Under MDD and IVDD Fall Away!

Today, on Monday, March 20, 2023, Regulation (EU) 2023/607 of the European Parliament and of the Council of March 15, 2023, amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards transitional provisions for certain medical devices and in vitro diagnostic medical devices, has been published in the Official Journal of the EU. The regulation introduces a longer transition period to adapt to the Regulation (EU) 2017/745 on medical devices (MDR). The new deadlines vary based on the medical devices' risk classification, and they work to ensure patients' continued access to medical devices. The regulation will also allow medical devices that are placed on the market in accordance with the current legal framework and that are still available to remain on the market (i.e., no 'sell-off' date).

### SIGNIFICANT EXTENSION OF THE TRANSITION PERIOD (MDD/MDR)

The regulation foresees a longer transition period for medical devices which have a certificate that was issued in accordance with the Council Directive 93/42/EEC concerning medical devices (MDD):

- **Class III devices** (other than custom-made implantable devices) may be placed on the market until **December 31, 2027**;
- **Class IIb implantable devices** (except sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors) may be placed on the market until **December 31, 2027**;
- **Class IIb devices** other than the above, may be placed on the market until **December 31, 2028**;



- **Class IIa devices** may be placed on the market until **December 31, 2028**;
- **Class I devices placed on the market in sterile condition or having a measuring function** may be placed on the market until **December 31, 2028**; and
- **Class I devices** for which the conformity assessment procedure pursuant to MDD did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to May 26, 2021 and **for which the conformity assessment procedure under the MDR requires the involvement of a notified body**, may be placed on the market until **December 31, 2028**.
- **Class I devices without sterile condition or measurement function** with a declaration of conformity under MDD without any involvement of a notified body placed on the market under the MDD before May 26, 2021 may be resold indefinitely. Since these Class I devices under MDD remain Class I devices under MDR, the declaration of conformity must be based on MDR since May 26, 2021.

Devices placed on the market until the above dates must meet the following conditions:

- the devices must continue to comply with the provisions of the MDD; with respect to post-market surveillance, market surveillance, vigilance, the registration of economic operators and of devices, devices must comply with MDR;
- there are no significant changes in the design and intended purpose;
- the devices do not present an unacceptable risk to the health or safety of patients, users or other persons, or to other aspects of the protection of public health;
- no later than May 26, 2024, the manufacturer has put in place a quality management system in accordance with the MDR;
- no later than May 26, 2024, the manufacturer has lodged a formal application for conformity assessment, and no later than September 26, 2024, the notified body and the manufacturer have signed a written agreement on the conformity assessment.

**Class III custom-made implantable devices** may be placed on the market until **May 26, 2026** without a MDR certificate issued by a notified body, provided that not later than May 26, 2024, the manufacturer has lodged a formal application for the applicable conformity assessment, and no later than September 26, 2024, the notified body and the manufacturer have signed a written agreement.

#### EXTENDED VALIDITY OF CERTIFICATES (MDD/MDR)

MDD certificates that were issued by notified bodies in accordance with the MDD as from May 15, 2017 that were valid on May 16, 2021 and that have not been withdrawn afterwards remain valid after the end of the period indicated on the certificate until the above dates.

Certificates that have expired before the date of entry of the amendment will be considered valid until the above dates if the manufacturer and a notified body have signed a written agreement for the conformity assessment procedure under MDR. Alternatively, the competent authority of a Member State may also grant a derogation from the applicable conformity assessment procedure.

#### CANCELLATION OF 'SELL-OFF' DATE (MDD/MDR AND IVDD/IVDR)

All products placed on the market under the MDD or the Directive 98/79/EC on *in vitro* diagnostic medical devices (IVDD) before May 26, 2021 may be resold indefinitely. Under the new regulation, the EU is also removing the 'sell-



off' date currently established in the MDR and the Regulation (EU) 2017/746 on *in vitro* diagnostic medical devices (IVDR). The 'sell-off' date is the end date after which devices that have already been placed on the market, and remain available for purchase, should be withdrawn. Removing this 'sell-off' date will ensure that the safe and essential medical devices that are already on the market remain available to healthcare systems and to patients in need.

### KEY TAKEAWAYS

The amendments associated with the new regulation should come as a sigh of relief for the medical device industry, as the bottleneck in the certification procedure caused many manufacturers to fear that they would not receive the required MDR certificates in time.

Entering into force on March 20, 2023, the regulation is binding in its entirety and directly applicable in all Member states.

King & Spalding's team of life sciences lawyers advises medical device manufacturers with business in the European Union and can advise on how to best address the legal issues involved. If you have questions, please contact Ulf Grundmann or Elisabeth Kohoutek for more information.

---

### ABOUT KING & SPALDING

Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,200 lawyers in 23 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients.

This alert provides a general summary of recent legal developments. It is not intended to be and should not be relied upon as legal advice. In some jurisdictions, this may be considered "Attorney Advertising." View our [Privacy Notice](#).

ABU DHABI	CHARLOTTE	FRANKFURT	LOS ANGELES	PARIS	SINGAPORE
ATLANTA	CHICAGO	GENEVA	MIAMI	RIYADH	TOKYO
AUSTIN	DENVER	HOUSTON	NEW YORK	SAN FRANCISCO	WASHINGTON, D.C.
BRUSSELS	DUBAI	LONDON	NORTHERN VIRGINIA	SILICON VALLEY	